Abstract: Described herein are methods of determining energy balance in individuals such as exercising individuals, individuals consuming a 13C-enriched test composition and individuals consuming a fixed diet with a known ?13C. The ?13C pre- and post-exercise, or pre- and post-consumption of the test beverage or fixed diet indicate whether the individual is in neutral or positive energy balance, or in energy deficit. The methods are particularly useful for individuals participating in weight management programs, and individuals under the care of health care professionals.

Abstract: Described herein are methods of determining energy balance in individuals such as exercising individuals, individuals consuming a 13C-enriched test composition and individuals consuming a fixed diet with a known ?13C. The ?13C pre- and post-exercise, or pre- and post-consumption of the test beverage or fixed diet indicate whether the individual is in neutral or positive energy balance, or in energy deficit. The methods are particularly useful for individuals participating in weight management programs, and individuals under the care of health care professionals.

Abstract: Described herein are methods of determining energy balance in individuals such as exercising individuals, individuals consuming a 13C-enriched test composition and individuals consuming a fixed diet with a known ?13C. The ?13C pre- and post-exercise, or pre- and post-consumption of the test beverage or fixed diet indicate whether the individual is in neutral or positive energy balance, or in energy deficit. The methods are particularly useful for individuals participating in weight management programs, and individuals under the care of health care professionals.

Abstract: The methods described herein are based on the observation that oscillations in breath isotope ratio data can be used for the purpose of identifying an “unhealthy” state in an organism such as a human. Described herein are methods of determining the state of health of an individual, such as the transition from healthy to infected, by identifying changes in oscillation modes in breath isotope ratio data. Changes in the frequency and/or amplitude of the oscillation modes are correlated with the heath of the individual. The methods can advantageously be used to provide information about the health of an individual in shorter periods of time than previous methods.

Abstract: The methods described herein are based on the observation that oscillations in breath isotope ratio data can be used for the purpose of identifying an “unhealthy” state in an organism such as a human. Described herein are methods of determining the state of health of an individual, such as the transition from healthy to infected, by identifying changes in oscillation modes in breath isotope ratio data. Changes in the frequency and/or amplitude of the oscillation modes are correlated with the heath of the individual. The methods can advantageously be used to provide information about the health of an individual in shorter periods of time than previous methods.

Abstract: The invention is methods and related kits for diagnosing a disease state of cachexia by measuring biomarker profiles from a biological sample. Rapid measurement of early onset or progression of the disease in a subject is determined by measuring biomarker levels from the subject and optionally comparing the biomarker levels to a standard biomarker profile or metabolome phase portrait for the disease. The biomarkers measured in the assay and related kit for cachexia progression include biomarkers selected from the group consisting of lactate, citrate, formate, acetoacetate, 3-hydroxy butrate, alanine, glutamine, glutamate, valine, isoleucine leucine, thrionine, lysine, arginine, tyrosine, phenyl alanine, histidine and tryptophan.

Abstract: The invention is methods and related kits for diagnosing a disease state of cachexia by measuring biomarker profiles from a biological sample. Rapid measurement of early onset or progression of the disease in a subject is determined by measuring biomarker levels from the subject and optionally comparing the biomarker levels to a standard biomarker profile or metabolome phase portrait for the disease. The biomarkers measured in the assay and related kit for cachexia progression include biomarkers selected from the group consisting of lactate, citrate, formate, acetoacetate, 3-hydroxy butrate, alanine, glutamine, glutamate, valine, isoleucine leucine, thrionine, lysine, arginine, tyrosine, phenyl alanine, histidine and tryptophan.